Bioproduction bottlenecks increasing due to staff shortages, says report

Image: iStock/zakokor

A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.

Image: iStock/zimmytws

Sanofi and Regeneron end ten-year mAb collaboration

iStock/Singkham

EMA bids to clarify API starting material info pharmas should provide

iStock/a-image

Artificial intelligence R&D to combat age-related diseases

iStock/agafapaperiapunta

Reprocell grows cell and tissue-based services in Scotland

See More Headlines

Markets & Regulations

iStock/Ruskpp

Avara agrees to buy ex-Hospira plant in Italy from Pfizer

iStock/farakos

Pfizer chooses Sanford, North Carolina site for $100m gene therapy plant

iStock/HYWARDS

US FDA clarifies what constitutes 'minor' change to biologic production process

See More in Markets & Regulations

Upstream Processing

Modular facilities solving Biopharma's capacity concerns. Image: c/o Alexander & Asher

Modular single-use facilities rebalance Biopharma’s capacity scales

Image: iStock/TeamOktopus

Seattle Genetics gains first production site through $43m BMS plant buy

iStock/Bet_Noire

Biotest relocates Florida plasma center, ups workforce

See More in Upstream Processing

Downstream Processing

iStock/media point inc

Trellis selects CMC Biologics to make mAb therapies

Image: c/o Repligen

Repligen closes Spectrum acquisition in latest boost for filtration business

Image: iStock/Manakin

Celltrion Healthcare $890m IPO to up biosimilar inventory and broaden portfolio

See More in Downstream Processing

Bio Developments

iStock/Paul-Daniel Florea

‘Origami pacman’ tech could help drug firms handle single-cells, say researchers

Image: iStock/artJazz

Kite assesses EU manufacturing options as it submits CAR-T therapy for review

Image: iStock/kasto80

Horizon cell line sequence released in bid to up bioproduction efficiency

See More in Bio Developments

Popular News

iStock/HYWARDS

US FDA clarifies what constitutes 'minor' change to biologic production process

Modular facilities solving Biopharma's capacity concerns. Image: c/o Alexander & Asher

Modular single-use facilities rebalance Biopharma’s capacity scales

Image: iStock/frender

Teva and Amgen latest to submit trastuzumab biosimilars to US FDA for review

Galleries

Videos

Audio

Latest Products

See more products